PharmaCyte Closing in on Submission of Crucial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
112
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application (IND) to the U.S. FDA.  It’s an IND that has been eagerly anticipated by the company’s shareholders since PharmaCyte met with the FDA in early 2017, and it would lay out PharmaCyte’s planned Phase 2b clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC. 

The key to submitting the IND is and always has been satisfying regulatory requirements.  In short, PharmaCyte must generate the necessary data that the FDA requires for any treatment—but especially a treatment that is deemed a “biologic” by the FDA and comprised of living cells that would be placed inside a human’s body.

PharmaCyte just announced that it has completed and passed 29 different tests from its Master Cell Bank (MCB), which is made up of cells that will be used in its planned clinical trial in patients with LAPC.  The successful completion of these tests is the final hurdle before encapsulation and testing of the encapsulated cells can begin at Austrianova.

Vials of cells from the MCB have already been supplied to the company’s partner, Austrianova, for encapsulation.  Austrianova will now be charged with completing the encapsulation process using PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box ® , to create the thousands of capsules that will be necessary to conduct its planned clinical trial.  Each capsule will contain 10,000 live cells, and then each syringe will be filled with 300 capsules—making up the finished product that will be sent to clinical trial sites.

The encapsulation process will be followed by a battery of tests that will generate the necessary data to satisfy regulatory requirements and should complete what has been a long, meticulous process and allow PharmaCyte to finally submit it’s IND to the FDA.

In addition to the 29 successful tests that PharmaCyte announced last week, the company has stated that a number of additional tests have also been a success (See www.PharmaCyte.com/news ).  This is all very good news for shareholders who have been clamoring for the start of a clinical trial, and it should bode well for a company that is trying to win the FDA’s approval when it does submit its IND.

PharmaCyte’s goal of starting a Phase 2b clinical trial to meet an unmet medical need in the treatment of patients with LAPC is a remarkable milestone for such a small company, and because their first ever trip inside the clinic involves presenting the FDA with a biologic treatment, the sheer complexity of this journey explains why the process has been so time consuming.  PharmaCyte’s treatment for LAPC utilizes genetically engineered live human cells that produce a particularly potent cytochrome P450 enzyme that is able to activate the chemotherapy prodrug ifosfamide. 

As previously mentioned, these cells are encapsulated using the Cell-in-a-Box ® technology, and the tiny, pinhead-sized capsules are implanted near the cancerous tumor so that a high local concentration of the cancer-killing ifosfamide metabolite is produced near the tumor. 

PharmaCyte’s treatment is not a single molecule drug.  It’s not a drug at all actually.  And because the treatment is made up of live human cells that are responsible for activating an already FDA-approved chemotherapy drug, the FDA expects every single cell to act exactly the same way, every single time, in every single test that PharmaCyte is required to conduct. 

The FDA simply wants to know that the capsules and the cells that live inside them will remain exactly the same at all times when they are eventually placed inside the human body.  And unfortunately there is no short cut when it comes to satisfying regulatory requirements.

The unmet medical need that PharmaCyte expects to address in its clinical trial is for those patients who no longer see any benefit from using the preferred standard of care, Abraxane ® combined with gemcitabine, or FOLFIRINOX, another combination chemotherapy that is increasingly being used in the U.S. as the preferred standard of care.  These patients must have tumors that no longer respond to these combination chemotherapies after they’ve been on the treatment for a period of between 4 and 6 months. 

The good news for PharmaCyte’s patient shareholders is that the company has reached the “end of the line” in what has been a very long process.  But, when it comes to the FDA and success in a clinical trial—especially for a small company like PharmaCyte—there is only one true shot at getting it right.

Stock Market Media Group will be interviewing PharmaCyte’s CEO, Kenneth L. Waggoner, and its Chief Scientific Officer, Prof. Dr. Walter H. Günzburg, to discuss the IND, encapsulation, testing, preparations for the upcoming planned clinical trial, among other topics.  The radio-style interview will be released and announced publicly via a press release within the next 2 weeks.

About Stock Market Media Group Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, radio-style CEO interviews and feature news articles.

This article was written based upon publicly available information. Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov , where you can also find all of PMCB’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about SPYR are not a recommendation to buy or sell a security.  Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that we were paid five thousand, seven hundred dollars from a third party via bank wire to produce content related to PharmaCyte.

For more information: www.stockmarketmediagroup.com .

Contact:

Stock Market Media Group

info@stockmarketmediagroup.com

Contact: Stock Market Media Group info@stockmarketmediagroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 15

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 53

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 95

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 103

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 20

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 62

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 0

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 6

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 42

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading